Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial

Table 2 Subgroup analysis according to sex and duration

Variables	Duration	Male (%)		Female (%)
Group A, ICU stay	< 10 d (71)	51 (65.3)	n = 78	20 (76.9)	n = 26
	11-20 d (30)	24 (30.76)		6 (23.1)
	21-30 d (3)	3 (3.8)		0 (0)
	≥ 31 d (0)	0 (0)		0 (0)
Group B, ICU stay	≤ 10 d (68)	55 (69.6)	n = 79	13 (52)	n = 25
	11-20 d (25)	16 (20.2)		9 (36)
	21-30 d (9)	8 (10.1)		1 (4)
	≥ 31 d (2)	0 (0)		2 (8)
Group A (n = 101), duration of total hospital stays	≤ 10 d (51)	37 (47.4)	n = 78	14 (53.8)	n = 26
	11-20 d (43)	33 (42.3)		10 (38.5)
	21-30 d (10)	8 (10.3)		2 (7.7)
	≥ 31 d (0)	0 (0)		0 (0)
Group B (n = 104), duration of total hospital stays	≤ 10 d (40)	31 (39.2)	n = 79	9 (36)	n = 25
	11-20 d (49)	40 (50.6)		9 (36)
	21-30 d (13)	8 (10.1)		5 (20)
	≥ 31 d (2)	0 (0)		2 (8)
Group A (n = 78), time to clinical improvement	≤ 10 d (50)	31 (55.4)	n = 56	19 (86.3)	n = 22
	11-20 d (24)	21 (37.5)		3 (13.6)
	21-30 d (4)	4 (7.1)		0 (0)
Group B (n = 73), time to clinical improvement	≤ 10 d (21)	20 (32.7)	n = 61	1 (8.3)	n = 12
	11-20 d (41)	34 (55.7)		7 (58.3)
	21-30 d (11)	7 (11.4)		4 (33.3)
Group A (n = 78), recovered cases, duration of ICU stay	≤ 10 d (49)	33 (59)	n = 56	16	n = 22
	11-20 d (27)	21 (37.5)		6
	21-30 d (2)	2 (3.5)		0
	≥ 31 d (0)	0 (0)		0
Group B (n = 73), recovered cases, duration of ICU stay	≤ 10 d (41)	37 (60)	n = 61	4 (33.3)	n = 12
	11-20 d (24)	16 (17)		8 (66.6)
	21-30 d (8)	8 (13)		0 (0)
	≥ 31 d (0)	0 (0)		0 (0)
Group A (n = 26), expired cases; Time to clinical failure/death	≤ 10 d (1)	1 (4.5)	n = 22	0 (0)	n = 4
	11-20 d (22)	18 (82)		4 (100)
	21-30 d (3)	3 (13.5)		0 (0)
Group B (n = 31), expired cases, time to clinical failure/death	≤ 10 d (27)	18 (100)	n = 18	9 (70)	n = 13
	11-20 d (1)	0 (0)		1 (7.5)
	21-30 d (1)	0 (0)		1 (7.5)
	> 31 d (2)	0 (0)		2 (15)
Group A (survived patients) (n = 78), time to symptomatic recovery	< 10 d (21)	20 (32.8)	n = 61	1 (8.3)	n = 12
	11-20 d (41)	34 (55.7)		7 (58.3)
	21-30 d (11)	7 (11.5)		4 (33.3)
	> 31 d (0)	0 (0)		0 (0)
Group B (survived patients) (n = 73), time to symptomatic recovery	< 10 d (3)	3 (3.91)	n = 61	0 (0)	n = 12
	11-20 d (45)	41 (67.2)		4 (33.3)
	21-30 d (19)	12 (19.7)		7 (58.3)
	>31 d (6)	5 (8.1)		1 (8.3)
Group A (n = 78) time to negative PCR recovery	11-20 d (41)		n = 56		n = 22
	21-30 d (32)
	31-40 d (5)
Group B (survived patients) (n = 73), time to negative PCR recovery	11-20 d (26)		n = 61		n = 12
	21-30 d (35)
	31-40 d (12)
Group A (n = 78), CT chest involvement on admission	< 20%	26 (46.4)	n = 56	15 (68.2)	n = 22
	21%-40%	16 (28.6)		5 (22.7)
	41%-60%	11 (19.6)		2 (9.0)
	> 61%	3 (5.3)		0 (0)
Group B (n = 73), CT chest involvement on admission	< 20	26 (42.6)	n = 61	3 (25)	n = 12
	21-40	22 (36)		7 (58.3)
	41-60	13 (21.3)		1 (8.3)
	> 61	0 (0)		1 (8.3)
Group A (n = 78), CT chest involvement during discharge	< 20	47 (83.9)	n = 56	16 (72.7)	n = 22
	21-40	9 (16)		6 (12.2)
Group B (n = 73), CT chest involvement during discharge	< 20	47 (77)	n = 61	8 (36.4)	n = 12
	21-40	14 (23)		4 (33.3)
Group A (n = 78), chest CT improvement	< 20	44 (74.6)	n = 56	19 (86.6)	n = 22
	21-40	5 (8.5)		3 (13.6)
	41-60	7 (11.9)		0 (0)
Group B (n = 73), CT improvement	< 20	54 (88.5)	n = 61	10 (83.3)	n = 12
	21-40	4 (6.6)		1 (8.3)
	41-60	3 (4.9)		1 (8.3)

ICU: Intensive care unit; CT: Computed tomography.